RxDoctor Payments Data

Richard Buck, MD

Medical Oncology · Sarasota, FLNPI 1609867472

Payments from drug & device makers

$2,573in general payments, 2019–2025

Across 116 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$322
  • Teva Pharmaceuticals USA, Inc.$317
  • Johnson & Johnson$285
  • AbbVie$262
  • Gilead$110
  • Takeda Pharmaceuticals U.S.A., Inc.$93
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$2,54399%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,573 in reported general payments places this provider in the 20th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$5,566,901
Medicare patients
929
Services billed
358,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide135$2,283,975
PomalystPomalidomide37$841,916
CalquenceAcalabrutinib Maleate46$674,636
ImbruvicaIbrutinib26$418,128
VenclextaVenetoclax44$383,330
XtandiEnzalutamide24$345,031
NinlaroIxazomib Citrate14$131,944
JakafiRuxolitinib Phosphate12$103,640
EliquisApixaban62$45,196
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$40,897
XareltoRivaroxaban25$19,572
Abiraterone Acetate21$2,677
Hydroxyurea75$1,509
Acyclovir54$886
Dexamethasone28$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$322$2,283,975135 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$73$841,91637 claims
AstraZenecaCalquence$21$674,63646 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$69$418,12826 claims
AbbVieVenclexta$262$383,33044 claims
Astellas Pharma US IncXtandi$64$345,03124 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Gammagard Liquid$93$172,84126 claims
Incyte CorporationJakafi$27$103,64012 claims
PfizerEliquis$59$45,19662 claims
Johnson & JohnsonXarelto$285$19,57225 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$317$88654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →